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anti-HCV compoundsThe hepatitis C virus (HCV) non-structural (NS) 5A protein plays an essential role in the replication of the viral
RNA by the membrane-associated replication complex (RC). Recently, a putative NS5A inhibitor, BMS-790052,
exhibited the highest potency of any known anti-HCV compound in inhibiting HCV replication in vitro and
showed a promising clinical effect inHCV-infected patients. The precisemechanism of action for this new class of
potential anti-HCV therapeutics, however, is still unclear. In order to gain further insight into its mode of action,
we sought to test the hypothesis that the antiviral effect of BMS-790052 might be mediated by interfering with
the functional assembly of theHCV RC.Weobserved that BMS-790052 indeed altered the subcellular localization
and biochemical fractionation of NS5A. Taken together, our data suggest that NS5A inhibitors such as BMS-
790052 can suppress viral genome replication by altering the proper localization of NS5A into functional RCs., Division of Gastroenterology
ne, CCSR 3115A, 269 Campus
3032.
n).
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Hepatitis C virus (HCV) is an important human viral pathogen
infecting more than 170 million people worldwide (Shepard et al.,
2005). HCV infection is responsible for the development of chronic
liver diseases such as liver cirrhosis and hepatocellular carcinoma
(Alter et al., 1999; Di Bisceglie, 2000). Current standard of care for
HCV infection using PEGylated interferon-α and ribavirin has
signiﬁcant toxicity and its efﬁcacy is suboptimal for many patients
(Liang et al., 2000; Zeuzem et al., 2000), emphasizing an urgent need
to develop alternative anti-HCV therapeutics.
HCV is a positive strand RNA virus and the only member of the
Hepacivirus genus of the Flaviviridae family. TheHCVgenome is composed
of a ~9.6 kb long single-stranded RNA, which encodes a polyprotein of
~3000 amino acids. This viral polyprotein undergoes proteolytic cleavage
by host and virally encoded proteases to yieldmore than 10 different viral
proteins (Grakoui et al., 1993a; Grakoui et al., 1993b). Among those viral
proteins, structural viral proteins such as E1, E2, and core serve as
components of the mature virus particle, whereas non-structural (NS)viral proteins such as NS3, NS4A, NS4B, NS5A, and NS5B serve as
components of a functional replication complex (RC) that replicates the
viral genomebut arenotpackaged intomaturevirusparticles (Blight et al.,
2000; Lohmann et al., 1999; Moradpour et al., 2007).
HCV replicates its RNAgenome in associationwithmembranes that
are derived in part from the endoplasmic reticulum (ER). Precisely
how this RC is assembled and maintained, however, remains largely
unknown. The NS5A protein is thought to play an essential role in the
assembly of the viral RC although its exactmolecular functions needed
for this process are still poorly characterized (Hijikata et al., 1993;
Moradpour et al., 1998). While enzymatic activities encoded in
other HCV non-structural proteins such as NS3 (protease) and NS5B
(RNA polymerase) (Manns et al., 2007) have enabled the develop-
ment of anti-HCV therapeutics against those targets, the lack of an
enzymatic activity described for NS5A has made the latter a more
challenging target against which to design speciﬁc anti-HCV drugs.
Recently, however, using a cell-based replicon screen a new class
of anti-HCV compounds was identiﬁed that appear to target NS5A
(Lemm et al., 2010). Surprisingly, one member of this class, BMS-
790052, showed the highest in vitro potency of any known anti-HCV
compound with a picomolar range of half-maximum effective
concentration (EC50) against HCV replicons from various genotypes.
In addition, this compound exhibited a very potent clinical effect on
patients chronically infected with HCV in a phase I clinical trial (Gao
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identiﬁed the ﬁrst 76 amino acids from NS5A as important de-
terminants for a replicon's susceptibility to NS5A inhibitors (Lemm
et al., 2010). Although BMS-790052 and related compounds were
reported to bind to NS5A from cell extracts and be associated with
decreased NS5A hyperphosphorylation, a correlate of genome
replication (Gao et al., 2010; Lemm et al., 2010; Neddermann et al.,
2004), the apparent Kd for NS5A binding appears to be signiﬁcantly
different than the EC50 for inhibition of viral replication leaving BMS-
790052's precise mechanism of action unclear.
In this report, we sought to test the hypotheses that BMS-790052
might exert its powerful anti-HCV effect in part by disrupting the proper
assembly of functional RCs or by direct inhibition of RCs. We used
morphologic and biochemical fractionation assays to show that BMS-
790052 alters the subcellular localization of NS5A protein without
affecting its expression level. We also determined that BMS-790052 has
no activity in assays for either in vitro replication activity of pre-
assembled RCs or NS5A self-dimerization. Taken together, our data
suggest that NS5A inhibitors like BMS-790052 suppress viral genome
replication by altering the subcellular localization of NS5A, thereby
preventing the assembly of NS5A into functional RCs.
Results
BMS-790052 blocks HCV genome replication
The NS5A inhibitors with a thiazolidinone core structure including
BMS-858 and BMS-824were originally identiﬁed by a cell-based high-
throughput HCV/bovine viral diarrhea virus (BVDV) replicon screen
(Lemm et al., 2010). They were further optimized by studying their
structure and activity relationship to yield BMS-790052 (Fig. 1A). This
compound is the most potent HCV replication inhibitor described to
date, with reported in vitro EC50 values of 9 and 71 pM against HCV
genotypes 1b and 2a, respectively. BMS-790052 also exhibited a high
therapeutic index (CC50/EC50) (N100,000), demonstrating its high
speciﬁcity against HCV and low toxicity to host cells (Gao et al., 2010).
Before embarking on our mechanism of action studies for BMS-
790052, we sought to conﬁrm its speciﬁcity and potency against HCV
genome replication. First, we examined its effect on transient HCV
replication. Huh7 cells transiently transfected with luciferase-linkedFig. 1. BMS-790052 blocks HCV genome replication. (A) Structure of BMS-790052. (B) Effect
cells harboring replicating subgenomic replicons derived from genotype 1b were treated wi
was prepared and an equal amount of each cell lysate was separated by SDS–PAGE. Levels o
monoclonal anti-NS5A and anti-β-actin antibodies. (C) Huh7.5 cells were infected with a vac
Bartman (Con1) plasmid construct containing the NS viral proteins downstream of a T7 prom
BMS-790052 for 9 h. A total cell lysate was prepared and an equal amount of each cell lysa
Western blot analysis using a monoclonal anti-NS5A antibody. (D) All procedures were perfo
blot analysis using a monoclonal anti-NS3 antibody.subgenomic replicon RNA (Blight et al., 2000; Elazar et al., 2003;
Tscherne et al., 2006) were treated with increasing doses of BMS-
790052. As expected, BMS-790052 displayed a very potent inhibitory
activity against transient HCV replication with an EC50 value of 1 pM
against genotype 1b replicon and 18 pM against genotype 2a J6/JFH
replicon, respectively (Supplementary Fig. 1). Assessment of antiviral
potency in the stable genotype 1b subgenomic replicon (Bart79I;
Elazar et al., 2003) was based on the detection of NS5A protein
content and yielded an EC50 of 15 pM (Fig. 1B), a value comparable to
the prior reported EC50 in the stable Con1 genotype 1b HCV replicon
system (Gao et al., 2010). In contrast to Con1, the Bart79I replicon
variant contains an adaptive mutation in the NS5A coding sequence,
which impairs hyperphosphorylation of NS5A (Blight et al., 2000).
While treatment of Con1 replicon cells with BMS-790052 resulted in a
reduced concentration of the intracellular hyperphosphorylated form
of NS5A as previously reported (Lemm et al., 2010), this effect could
not be observed in Bart79I replicon cells (Fig. 1C); yet BMS-790052
remained a highly potent inhibitor of HCV replication in these cells,
suggesting that inhibition of hyperphosphorylation may not be a sole
mechanism of action for NS5A inhibitors. Taken together, these data
conﬁrmed that BMS-790052 is a potent inhibitor of both transient as
well as stable HCV genome replication.
BMS-790052 alters the subcellular localization of NS5A
Having conﬁrmed the extraordinary potency of BMS-790052
against HCV replication, we next sought to study its mechanism of
action. Since NS5A plays an essential role in the assembly of the viral
RC, we hypothesized that BMS-790052 disrupts NS5A function(s)
important for this assembly process. To test this hypothesis, we used a
vaccinia virus-based HCV replicase assembly system to express and
assemble NS proteins into RCs in the presence or absence of BMS-
790052. In this system, the HCV non-structural proteins NS2 to NS5B
are constitutively expressed via a T7 RNA polymerase promoter, with
a vaccinia virus recombinant that provides a source of T7 RNA
polymerase. This allows the study of HCV RC assembly without
interference from HCV replication inhibition.
First, we examined the effect of BMS-790052 on the subcellular
localization pattern of NS5A proteins using immunoﬂuorescence
analysis. As shown in Fig. 2Ai, when NS5A protein was expressed inof BMS-790052 on stable replication of a HCV replicon derived from genotype 1b. Huh7
th 0, 0.1, 1, 10, 100, or 1000 pM of BMS-790052 for 3 days. A total cell lysate from cells
f NS5A and β-actin protein expression were examined by Western blot analysis using
cinia virus expressing a T7 RNA polymerase and then transfected with either Bart79I or
oter. Transfected cells were incubatedwith 0.1% of DMSO or 0.01, 0.1, 1, 10, or 100 nM of
te was separated by SDS–PAGE. Levels of NS5A protein expression were examined by
rmed as in (C) except that levels of NS3 protein expression were examined byWestern
Fig. 2. BMS-790052 alters the subcellular localization of NS viral proteins. (A) Immunoﬂuorescence analysis of NS5A. Huh7.5 cells were infected with a vaccinia virus expressing a T7
RNA polymerase and then transfected with a plasmid (Bart79I) expressing the HCV NS viral proteins downstream of a T7 promoter. Transfected cells were incubated with 0.1% of
DMSO (i), 100 pM (ii), or 1 nM of BMS-790052 (iii) for 9 h. Cells were ﬁxed, permeabilized, and stained with a monoclonal anti-NS5A mouse antibody. Anti-mouse Alexa 488-
conjugated secondary antibody was used to visualize the NS5A protein in green. White scale bar represents 10 μm. The image on the right panel shows 4-fold enlarged view of the
area marked with a white rectangle on the left panel, highlighting the differences in distribution patterns of NS5A. (B) Immunoﬂuorescence analysis of NS5B. Procedure was
performed as described in Fig. 2A, except that cells were stained with a polycolonal anti-NS5B rabbit antibody. Anti-rabbit Alexa 488-conjugated secondary antibody was used to
visualize the NS5B protein in green. (C) Immunoﬂuorescence analysis of NS3. Procedure was performed as described in (A) except that cells were stained with a monoclonal anti-
NS3 mouse antibody. Anti-mouse Alexa 488-conjugated secondary antibody was used to visualize the NS3 protein in green. (D) Immunoﬂuorescence analysis of PDI. Procedure was
performed as described in (A) except that cells were stained with a polyclonal anti-PDI rabbit antibody. Anti-rabbit Alexa 594-conjugated secondary antibody was used to visualize
the PDI protein in red.
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Fig. 3. Reversal of BMS-790052-induced alterations on subcellular localization of NS
proteins expressed from a replicon containing the BMS-790052-resistant mutation
(Y93H) in NS5A. (A) Immunoﬂuorescence analysis of NS5A. Procedure was performed
as described in Fig. 2A except that Bart79I plasmid, containing the BMS-790052-
resistant mutation Y93H (NS5A), was used to express NS viral proteins. (B) Immuno-
ﬂuorescence analysis of NS5A. Procedure was performed as described in Fig. 2A except
that the plasmid used was pEF6-NS5A, which expresses NS5A by itself.
13Rapid Communicationthe context of the HCV NS proteins, it was localized in large
perinuclear and cytosolic foci (Fig. 2Ai). However, in cells treated
with BMS-790052, NS5A protein showed a diffuse localization pattern
(Fig. 2Aii and iii). Other NS proteins, however, were minimally
affected. NS5B protein was localized in large foci in the absence of
compound (Fig. 2Bi), and its localization pattern did not change even
in the presence of BMS-790052 (Fig. 2Bii and iii). The localization
pattern of NS3 protein, which is less punctate than that of NS5A and
NS5B proteins, was minimally affected by treatment of BMS-790052
(Fig. 2C). In addition, the subcellular localization of the ER marker
protein, PDI, did not show any signiﬁcant change upon treatmentwith
BMS-790052 (Fig. 2D). We also observed co-localization of NS5A
protein, when expressed exogenously in the context of the HCV
polyprotein by using the vaccinia virus-based HCV replicase assembly
system, with NS5A protein expressed endogenously in HCV replicon
cells (Supplementary Fig. 2). The subcellular localization of NS5A
expressed from the vaccinia virus-based HCV replicase assembly
system was therefore similar to that observed in cells harboring HCV
replicons.
A Y93H mutation within NS5A was identiﬁed to be one of the
major mutations conferring a 20-to 1000-fold resistance to BMS-
790052 and related compounds, depending on which HCV genotype
was assayed (Fridell et al., 2010; Gao et al., 2010). Therefore, we
hypothesized that if the BMS-790052-induced alteration in the
subcellular localization of NS proteins is required for its inhibition of
HCV genome replication, the resistance variant (Y93H) should reverse
this alteration at comparable concentrations of compound. To test this
hypothesis, the Y93H mutation was introduced into the vaccinia
virus-based HCV replicase assembly system and the effect of
BMS-790052 on NS5A protein subcellular localization was examined.
BMS-790052-resistant mutant NS5A protein (NS5A-Y93H) was
localized into large foci, similar to wild-type NS5A protein, when
expressed in the context of HCV NS proteins in the absence of
compound (Fig 3Ai). Consistent with the above hypothesis,
NS5A-Y93H protein was resistant to the BMS-790052 effect and
remained localized in the large foci without showing diffuse
localization patterns in the presence of BMS-790052 at up to 1 nM
(Fig. 3Aii and iii). These data suggest that the Y93H mutation in NS5A
confers resistance to BMS-790052 by preventing the drug's ability to
alter the subcellular localization of NS5A protein. Just as the resistance
to replication inhibition conferred by the Y93H mutation can be
overcome with higher concentrations of BMS-790052, diffuse local-
ization patterns of NS5A protein started to be observed with the
replicon containing the NS5A Y93H resistance mutation when the
concentration of BMS-790052 was increased higher than 100 nM
(Supplementary Fig. 3A).
Next, we sought to test whether the BMS-790052 induced
alterations in the subcellular localization of NS proteins occurred
when the proteins were expressed individually, as opposed to in the
context of the HCV polyprotein. Interestingly, when NS5A was
expressed in isolation, most of the NS5A proteins were diffusely
localized throughout the cytoplasm (Fig. 3Bi), and this dispersed
localization pattern was not affected by BMS-790052 (Fig. 3Bii). This
suggests that the BMS-790052-induced alteration in subcellular
localization of NS5A protein only takes place when NS5A protein is
co-expressed with other NS proteins in the context of the viral
polyprotein.
The BMS-790052-induced alteration in subcellular localization of NS5A
protein is independent of NS protein expression levels
The observed BMS-790052-induced alteration in subcellular
localization of NS5A protein might be the result of drug-induced
changes in expression levels of NS proteins. To address this possibility,
we performedWestern blot analyses to examine the expression levels
of both NS5A and NS3 proteins in the presence of increasingconcentrations of BMS-790052 in the vaccinia virus-based HCV
replicase assembly system. As shown in Fig. 1C and D, BMS-790052
does not signiﬁcantly affect the level of NS5A or NS3 expression at
concentrations up to 100 nM. This suggests that the BMS-790052-
14 Rapid Communicationinduced alterations in the subcellular localization of NS5A protein
were not caused by reduced expression levels of NS proteins.
BMS-790052 alters the subcellular fractionation patterns of NS5A
protein
The observation of BMS-790052-induced alterations in the subcel-
lular localization of NS5A protein implies changes in the molecular
interactions of NS5A proteinwith other viral proteins or host factors in
the presence of BMS-790052. We therefore examined whether BMS-
790052 alters the biochemical subfractionation patterns of NS proteins
including NS5A and NS3. For this purpose, a whole cell lysate from the
vaccinia virus-based HCV replicase assembly system was prepared in
the absence or presence of 10 nM of BMS-790052. Cell lysates were
fractionated on idioxanol density gradients (Vogelmann and Nelson,
2007) and the amounts of NS5A and NS3 proteins within the various
gradient fractions were determined by Western blot analysis. As
shown in Fig. 4A, most of the NS5A protein was found to be
concentrated in middle fractions (numbers 10–15), which correspond
to intermediate density fractions. In the presence of BMS-790052,
however, the distribution of NS5A was signiﬁcantly shifted from the
middle to the top, low density, fractions (numbers 1–8) (Fig. 4B). In
contrast, the density gradient proﬁles of NS3 protein as well as control
cell–cell adhesion protein E-cadherin were not signiﬁcantly affected
by treatment with 10 nM of BMS-790052. Thus there is morphologic
and biochemical evidence that BMS-790052 induces a speciﬁc
alteration in the subcellular distribution of NS5A protein and the
resulting effect on the assembly of the HCV RCs may underlie BMS-
790052's mode of suppressing HCV genome replication.
BMS-790052 affects neither the in vitro replicase activity of
pre-assembled RCs nor the self-dimerization of NS5A proteins
If a potential mechanism of action for BMS-790052 involves
inhibition of proper assembly of a new viral RC by altering theFig. 4. BMS-790052 alters the subcellular fractionation patterns of NS proteins. Huh7.5 cells w
with a plasmid (Bart79I) containing the NS viral proteins downstream of a T7 promoter. Tran
Membrane-enriched cell lysates were prepared and fractionated on idioxanol density grad
Western blot analysis using anti-NS5A, anti-NS3, and anti-E-cadherin antibodies.localization of NS5A, we would predict that already assembled RCs
might be insensitive to the effects of the drug. To test this hypothesis,
the in vitro replicase activity (RNA synthesis activity) of membrane-
associated RCs (Ma et al., 2005) was determined in the presence or
absence of BMS-790052 using RCs isolated from Huh7.5 cells
harboring a full-length J6/JFH (genotype 2a) replicon. As shown in
Fig. 5A, in the absence of drug, robust in vitro RNA synthesis activity
was detected. A total of 10 μM of a chain-terminating nucleotide
analog 3′-deoxycytidine triphosphate (3′-dCTP) completely inhibited
HCV replicase activity, similar to previously reported data (Ma et al.,
2005). In contrast, BMS-790052 failed to inhibit HCV replicase activity
even at micromolar concentrations. This suggests that BMS-790052 is
not able to affect pre-assembled RCs.
High resolution structural studies of NS5A protein reveal that
the protein forms a dimer via contacts near the N-terminus, and
the Y93H resistance mutation lies at the interface between two
NS5A proteins (Tellinghuisen et al., 2005). We therefore hypothe-
sized that BMS-790052 might inhibit RC assembly and HCV
replication by interfering with self-dimerization of NS5A proteins.
To test this hypothesis, we utilized a mammalian two-hybrid system.
Sequences encoding a VP16 transactivation domain and a Gal4 DNA-
binding domain were each individually fused to the N-terminus of
NS5A so as to express VP16–NS5A and Gal4DBD–NS5A fusion
proteins, respectively. Interactions of these two molecules were
measured by a luciferase reporter driven by a promoter containing
ﬁve Gal4 binding sites (Fearon et al., 1992). As shown in Fig. 5B, a
robust interaction between the two NS5A fusion proteins was
detected in DMSO-treated control cells. Their level of interaction
was comparable to that of two positive control proteins, MyoD
(myogenic regulatory protein) and ID (negative regulator ofmyogenic
differentiation) (Weintraub et al., 1991). However, the NS5A–NS5A
interactionwas not affected by treatment with 10 nM of BMS-790052.
This suggests that BMS-790052 may exert its effects of inhibiting
functional RC assemblies by means other than interfering with NS5A
dimerization.ere infectedwith a vaccinia virus expressing a T7 RNA polymerase and then transfected
sfected cells were incubated with 0.1% of DMSO (A) or 10 nM of BMS-790052 (B) for 9 h.
ients. Distribution patterns of NS5A, NS3, and E-cadherin proteins were examined by
Fig. 5. BMS-790052 affects neither the in vitro replicase activity of pre-assembled RCs
nor the self-dimerization of NS5A proteins. (A) Effects of BMS-790052 on an in vitro
replicase activity from pre-assembled RCs from genotype 2a. 10 μM of 3′-dCTP, 0.1% of
DMSO, 1 or 10 μM of BMS-790052 was incubated with a crude membrane fraction
isolated from Huh7.5 cells harboring replicating J6/JFH full-length replicons derived
from genotype 2a. Newly replicated HCV RNAs were separated on an agarose gel and
exposed to a phosphorimager. (B) Effects of BMS-790052 on the dimerization of NS5A
proteins. Equal amounts of pAct-NS5A, pBind-NS5A and pG5-Luc were transfected into
Huh7.5 cells. Transfected cells were incubated with 0.1% of DMSO or 10 nM of BMS-
790052. Fireﬂy luciferase assay was performed to measure levels of interaction
between two NS5A fusion proteins. pAct and pBind are negative control vectors and
pAct-Myo and pBind-ID are positive control vectors.
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In this study, we conﬁrmed the extraordinary potency of the
putative NS5A inhibitor BMS-790052 against HCV RNA genome
replication. In order to gain further insight into its mechanism of
action, we investigated the effect of BMS-790052 on the function and
on the assembly of functional HCV RCs. To allow the investigation of
inhibitors on RC assembly without interference from HCV replication
inhibition, we used a vaccinia virus-based HCV replicase assembly
system, which expresses T7 RNA polymerase and HCV non-structural
proteins NS2 to NS5B under the control of the T7 RNA polymerase
promoter. Using this system, we found that NS5A protein localizes to
large foci in Huh-7 cells. BMS-790052 altered the subcellular
localization of RC-associated NS5A protein, as assessed both morpho-
logically by immunoﬂuorescence and biochemically by subcellular
fractionation. Interestingly, this occurred only when NS5A protein
was co-expressed with other NS proteins in the context of the HCV
polyprotein, suggesting that interactions between HCV NS proteins
that contribute to RC formation are a prerequisite for the formation of
large foci and for inhibition of HCV replication by BMS-790052. These
data suggest that the NS5A inhibitor BMS-790052 exerts its potent
anti-HCV replication activity by targeting NS5A function(s) or
interactions that are essential for the formation of functional RCs.
While an in vitro EC50 value of BMS-790052 against genotype 1b
replicon transient HCV replicationwas determined to be around 1 pM,
15 pM of BMS-790052 was required to reduce stable HCV replication
in half (Fig. 1B). This difference in relative potency may be explained
by the presence of pre-assembled RCs in the stable replicon, but not in
the transient replicon system. As BMS-790052 only inhibits the
formation of new RCs, a complete inhibition of HCV replication may
depend on RCs turnover in stable replicon-harboring cells.With regards to RCs stability, we were able to observe reduction in
the amount of NS5A protein close to undetectable levels when stably
HCV replicating cells were treated with 1 nM of BMS-790052 for
3 days (Fig. 1B). Similarly, administering NS3 protease inhibitor to
HCV replicon cells was shown to eliminatemost of NS3 protein within
3 days (Pause et al., 2003). In addition, it has been shown that the half
life of NS5A protein in HCV replicon cells is around 16 h as measured
by pulse-chase experiments (Pietschmann et al., 2001). In spite of
their different mechanisms of action, both NS5A inhibitors and NS3
protease inhibitors appear to act primarily on the new assembly of
functional viral RCs without affecting the pre-existing viral RCs.
Unlike NS3 protease inhibitors, however, which block the synthesis of
new viral proteins through inhibition of polyprotein processing, the
NS5A inhibitor does not directly affect the expression of viral proteins
(Fig. 1C and D).
BMS-790052 altered the subcellular localization of NS5A protein
from large foci to a diffuse localization pattern (Fig. 2A and B). The
dose response of this effect with regards to compound concentration
was different in the HCV replicon system and in the T7-RNA
polymerase based HCV RC assembly system. In the replicon system,
BMS-790052 inhibited HCV replication at low pM concentrations,
while in the T7-polymerase driven RC assembly system, a BMS-
790052 concentration of 100 pM and above was required to induce
the phenotypic effect of subcellular localization change. The differ-
ence in effective BMS-790052 concentration between the transient
replicon and the stable replicon was 5- to 15-fold, and between the
stable replicon and the T7 RNA polymerase systemwas approximately
17-fold. We found that the T7-RNA polymerase-based HCV RC
assembly system produces 3- to 4-fold higher levels of viral NS
proteins compared with those found in HCV replicon cells due to its
continuous production of HCV RNAs by a robust T7 RNA polymerase
activity (data not shown). Therefore, relatively higher concentrations
of BMS-790052 might be needed in order to achieve a similar level of
inhibition in the T7 RNA polymerase-based viral RC assembly system
as compared to the replicon system. The difference in phenotypic
sensitivity between the transient and the stable replicon systems may
be due to the presence of pre-assembled RCs in the latter, which are
not affected by BMS-790052.
In regards to its mode of action, reduction of the NS5A hyperpho-
sphorylation by BMS-790052 was reported to be correlated with its
anti-HCV replication activity (Lemmet al., 2010).We alsowere able to
see a reduction of hyperphosphorylated NS5A by half upon treatment
of 100 pM of BMS-790052 in the subgenomic Con1 replicon system
(Fig. 1C). However, replication of the Bart79I HCV 1b replicon, which
carries the adaptive mutation S232I in NS5A that signiﬁcantly
decreases the level of hyperphosphorylated NS5A (Blight et al.,
2000) was similarly sensitive to inhibition with BMS-790052 as was
the Con1 replicon. This indicates that inhibition of hyperphosphor-
ylation may not be a sole mechanism of action for NS5A inhibitors.
The subcellular localization of NS5A when expressed by itself is
found to be diffuse in the cytoplasm of Huh-7 cells (Fig. 3B), indicating
that other NS and/or host proteins are involved in targeting NS5A
to large foci. We also observed that exogenously expressed NS5A
protein in isolation driven by a CMV promoter does not colocalize
with NS5A protein that is endogenously expressed from HCV
replicons and incorporated into viral RCs (data not shown). When
NS5A protein is expressed in the context of the HCV polyprotein by
using the T7 RNA polymerase virus-based RC assembly system,
however, such exogenously expressed NS5A colocalized with endog-
enous, HCV replicon-expressed NS5A (Supplementary Fig. 2). This
suggests that expression and assembly of NS proteins by the T7 RNA
polymerase-based RC assembly system is accurately mimicking
the subcellular localization patterns of NS protein in HCV replicon
cells.
The results of biochemical subcellular fractionation assays showed
that BMS-790052 treatment of Huh-7.5 cells expressing HCV NS
16 Rapid Communicationproteins induced the redistribution of NS5A from middle density
fractions to low density fractions (Fig. 4A and B). Treatment with
BMS-790052 was therefore associated with both morphologic and
biochemical alterations in the subcellular distribution of NS5A, as
observed by immunoﬂuorescence analysis and subcellular fraction-
ation assays, respectively, consistent with a change in NS5A protein
interactions with viral or host factors.
Mutations that confer resistance to BMS-790052 have been
mapped to residues 28–32 and 93 of NS5A (Fridell et al., 2010;
Lemm et al., 2010), suggesting that BMS-790052 may disrupt an
unknown function of the NS5A N-terminus, that is required for
interaction with other NS proteins or host factors to allow localization
in the large foci. Amino acids 1–30 of NS5A serve as a membrane
anchor, and likely contribute to localizing NS5A to an ER-derived
membrane, where the HCV RC is likely formed (Brass et al., 2002;
Elazar et al., 2003; Moradpour et al., 1998). Although we found no
evidence that BMS-790052 can prevent NS5A dimerization, the
compound may affect the NS5A dimer conformation without
preventing dimer formation or disrupt the interaction of NS5A with
as yet unidentiﬁed host and/or viral proteins that are important for
building RC assemblies. Therefore, the identiﬁcation of NS5A-binding
host and viral proteins which may be affected by NS5A inhibitors like
BMS-790052 could provide important insights into understanding RC
assembly and the detailed mechanism of action for BMS-790052 and
related inhibitors.
Taken together, we found that BMS-790052, a representative of an
exciting new class of putative NS5A inhibitors, induces alterations in
the subcellular localization of NS5A protein from large foci to a diffuse
cytoplasmic localization. The point mutant NS5A-Y93H protein
confers resistance to the BMS-790052 induced effect on subcellular
localization of NS5A. We propose therefore that BMS-790052 pre-
vents the incorporation of NS5A into functional HCV RCs, while pre-
formed RCs are not affected by BMS-790052. Together with other
direct-acting antivirals, such as NS3 protease inhibitors, NS5B
polymerase inhibitors, and NS4B inhibitors, NS5A inhibitors may
provide a valuable component of future combination therapy against
HCV infection. Therefore, a better understanding of the mechanism of
action of this new class of anti-NS5A therapeutics will help develop
new anti-HCV strategies and better understand the essential role of
NS5A in the assembly process of viral RCs.
Materials and methods
Synthesis of BMS-790052
BMS-790052 was synthesized by Roche according to the pro-
cedures described in Bachand, C. et al. Hepatitis C virus NS5A in-
hibitors, world patent WO-2008021927 (2008).
Plasmids
Bartman is a high-efﬁciency bicistronic subgenomic replicon of
HCV derived from an HCV genotype 1b Con1 sequence that harbors
the neomycin phosphotransferase gene in the ﬁrst cistron and the
HCV nonstructural proteins in the second cistron under the
translational control of an EMCV IRES (Blight et al., 2000). Bart79I is
a modiﬁcation of Bartman that contains an adaptive mutation
(S2204I) in NS5A, which increases replication efﬁciency (Blight
et al., 2000). Bart79I-luc is a modiﬁcation of the Bart79I subgenomic
replicon wherein the neomycinphosphotransferase gene of the ﬁrst
cistron has been replaced by a ﬁreﬂy luciferase reporter gene from
pGL3 (Promega). Construction of Bart79I-luc was described else-
where (Bryson et al., 2010), and construction of pEF6-NS5A, which
expresses NS5A under the transcriptional control of the elongation
factor 6 promoterwas also described elsewhere (Sklan et al., 2007). To
introduce an BMS-790052-resistant mutation (Y93H) in NS5A intoBart79I, the nucleotide sequence TAC that encodes for tyrosine at
amino acid position 93 of NS5A (at nucleotide position 4009 of
Bart79I) was changed to CAC (encoding for histidine) using the
following two primers FW-NS5A-Y93H, 5′-CATTCCCCATTAACGCGCA-
CACCACGGGCCCCTGCAC-3′, and RV-NS5A-Y93H, 5′-GTGCAGGGG-
CCCGTGGTGTGCGCGTTAATGGGGAATG-3′ through the use of Quick-
Change™ XL site-directed mutagenesis kit (Stratagene) as described
by the manufacturer. FL-J6/JFH-5′C19Rluc2AUbi is a monocistronic,
full-length HCV genome that expresses Renilla luciferase and was
derived from the previously described infectious genotype 2a HCV
genome J6/JFH1 (Lindenbach et al., 2005). pAct and pBind are vectors
to express fusion proteins with a VP16 transactivation domain and a
Gal4 DNA-binding domain, respectively. pG5-Luc is a reporter
plasmid containing ﬁve Gal4 DNA-binding sites. They are commer-
cially available checkmate vectors (Promega) to perform a mamma-
lian two-hybrid experiment. pAct-Myo and pBind-ID are positive
control vectors provided with the kit. pAct-NS5A and pBind-NS5A
were constructed by cloning the NS5A DNA fragment ampliﬁed by
PCR from Bart79I into pAct and pBind plasmids by using XbaI and NotI
sites, respectively.
Cell culture
Huh7.5 cell line of the human hepatoma origin were cultured
in monolayers as described (Blight et al., 2002; Sklan et al., 2007),
with media consisting of DMEM (Mediatech) supplemented with 1%
L-glutamine (Mediatech), 1% penicillin, 1% streptomycin (Mediatech),
and 10% fetal bovine serum (Omega Scientiﬁc). The establishment of
Bart-HA cells (Huh7 cells harboring a subgenomic 1b replicon with an
HA tag inserted in frame into the C-terminal segment of NS5A) was
described elsewhere (Sklan et al., 2007).
Immunoﬂuorescence microscopy
Huh7.5 cells were grown on coverslips to 70% conﬂuency.
Coverslips were rinsed in phosphate-buffered saline (PBS) three
times. After a vaccinia virus infection and a transfection, cells were
ﬁxed at room temperature for 15 min in 4% paraformaldehyde,
permeabilized in 0.1% Triton-X in PBS for 5 min, rinsed three times in
PBS, and blocked with PBS with 2% fetal bovine serum (FBS). Anti-
NS5A (1:1000, 6F3, Virostat, Portland, ME), anti-NS3 (1:1000, 6D7,
Virostat, Portland, ME), anti-NS5B (1:200, house-made by Roche), or
anti-PDI antibodies (1:500, SPA-890, Enzo Life Sciences, Plymouth
Meeting, PA) were applied, and the mixture was incubated for 2 h.
After three washes in PBS, coverslips were incubated with Alexa 488-
conjugated anti-mouse or Alexa 594-conjugated anti-rabbit IgG
secondary antibodies (Invitrogen, Carlsbad, CA) for 1 h. Following
three washes with PBS, coverslips were mounted onto slides using
Prolong Gold anti-fade reagent with DAPI (Invitrogen, Carlsbad, CA)
and sealed. Fluorescent signals were examined and captured by LSM
510 Carl Zeiss confocal laser scanning microscope.
Transient replication assays
Transient replication assays were performed as previously de-
scribed (Cho et al., 2010). Brieﬂy, Huh7.5 cells were trypsinized and
resuspended at 1.5×107 cells per ml in PBS buffer. A total of 5 μg of in
vitro transcribed Bart79I-luc or FL-J6/JFH-5′C19Rluc2AUbi RNAs were
mixed with 400 μl of Huh7.5 cells in a 2-mm-gap cuvette (BTX) and
immediately pulsed (0.68 kV (Bart79I-luc) and 0.82 kV (FL-J6/JFH-5′
C19Rluc2AUbi) and, ﬁve 99 ms pulses) with a BTX-830 electroporator.
Pulsed cells were immediately diluted into 20 ml of pre-warmed
growth medium and seeded in 96-well plates (17,000–20,000 cells
per well). At 6 h after electroporation, different concentrations of
BMS-790052 were added to the cells. After 72 h of treatment, cells
were incubated for 2 h at 37 °C in the presence of 10% Alamar Blue
17Rapid Communicationreagent (TREK Diagnostic Systems) to assess cytotoxicity. Plates were
then scanned and ﬂuorescence was detected by using a FLEXstation II
384 (Molecular Devices, Sunnyvale, CA). Viral RNA replication was
determined using ﬁreﬂy (Bart79I-luc) or Renilla (FL-J6/JFH-5′C19Rlu-
c2AUbi) luciferase assays (Promega).
Stable replication assays
The establishment of Huh7.5 cells stably maintaining a Bart79I
subgenomic replicon in the presence of G418 selection was described
elsewhere (Cho et al., 2010). Brieﬂy, in vitro-transcribed Bart79I RNAs
were electroporated into Huh7.5 cells. The electroporated cells were
supplemented with G418 to a ﬁnal concentration of 750 μg/ml. This
selection medium was replaced every 3 days for 3 weeks. Different
concentrations of BMS-790052 were added to the G418-resistant
Huh7.5 cells for 3 days.
Infection and transfection expression
Infection and transfection was performed as previously described
(Elazar et al., 2003). Brieﬂy, a vaccinia virus that expresses the T7 RNA
polymerase was used to infect Huh7.5 cells at a multiplicity of
infection (MOI) of 10. After 45 min of incubation at 37 °C, the cells
were washed twice with Opti-MEM (Invitrogen) and subjected to
transfection with Bart79I plasmids containing the T7 promoter. The
cells were supplemented with growth media containing DMSO or
different concentrations of BMS-790052 and incubated for 9 h at 37 °C
followed by Western blot and immunoﬂuorescence analyses.
Western blot analysis
Whole-cell extracts were prepared in RIPA buffer (150 mM NaCl,
50 mM Tris/HCl (pH 8.0), 5 mM EDTA, 0.5 mM dithiothreitol, 100 mM
sodium ﬂuoride, 200 mM sodium orthovanadate, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS, and 1 mM PMSF) containing a
cocktail of protease inhibitors (Complete, Mini; Roche Diagnostic at
ﬁnal concentration of 1 tablet per 10 ml RIPA buffer) and quantitated
by the Bradford assay (Bio-Rad). Equal amounts of protein were
electrophoresed on an SDS–polyacrylamide gel, subsequently trans-
ferred to a polyvinylidene diﬂuoride membrane (Immobilon-P;
Millipore, Bedford), and probed with a mouse anti-NS5A or anti-
NS3monoclonal antibodies (1:1000, 6F3 for NS5A and 1:1000, 6D7 for
NS3, Virostat, Portland, ME). Proteins were visualized via enhanced
chemiluminescence (GE healthcare).
Subcellular fractionation assays
Subcellular fractionation assays using an idioxanol gradient were
performed as described previously (Vogelmann and Nelson, 2007).
Brieﬂy, transfected cells were washed three times with ice-cold
Ringers solution (10 mMHEPES–NaOH, pH 7.4, 154 mMNaCl, 7.2 mM
KCl, 1.8 mM CaCl2). Then, cells were cross-linked by treatment of
200 μg/ml of Dithiobis (succinimidylpropionate, Pierce Biotechnology
Inc.) for 20 min. A cross-linking reactionwas stopped by rinsingwith a
quenching buffer (120 mM NaCl, 10 mM Tris–HCl, pH 7.4, 50 mM
NH4Cl). Total cell lysates were prepared in a homogenization buffer
(20 mM HEPES KOH, pH 7.2, 90 mM K-acetate, 2 mM Mg-acetate,
25 mMsucrose, 300 nMPefabloc and a protease inhibitor cocktailMini
(Roche)) by using a ball-bearing homogenizer with 0.3747′ ball and
spun down at 930×g for 10 min at 4 C to pellet nuclei and unbroken
cells. Remaining supernatantwas loaded on top of 10%, 20%, and 30% of
idioxanol gradients and was ultra-centrifuged at 350,000×g for 3 h
5 min using Beckman Vti65.1rotor. After a centrifugation, 0.5 ml of a
protein–idioxanol mixture was retrieved from top to bottom to make
total 24 fractions. Total proteins were precipitated in each fraction by
using methanol and chloroform for Western blot analysis.In vitro replicase assay
Cytoplasmic membrane fractions were prepared from Huh7.5
derived cell line containing an autonomously replicating HCV
subgenomic replicon (J6/JFH for 2a genotype) as follows. Cell rupture
and cytoplasmic membrane fraction isolation were performed as
previously described (Takeda et al., 1986). In vitro replicase assay was
performed as previously described (Ma et al., 2005). Brieﬂy, the
standard replicase assay reactions contained 10 μl cytoplasmic
membrane fraction, 50 mM HEPES, pH 7.5, 10 mM KCl, 10 mM DTT,
5 mMMgCl2, 20 μg/ml actinomycin D, 1 mMATP, GTP, and UTP, 30 μCi
[α-
32
P]-CTP (3000 Ci/mmol, 10 mCi/ml), 1 U/Al SUPERase.In
(Ambion), 10 mM creatine phosphate, and 200 μg/ml creatine
phosphokinase in a ﬁnal volume of 25 μl. BMS-790052 was added to
make a ﬁnal concentration of 1 μM and 10 μM, respectively. A total of
10 μM of a chain-terminating nucleotide analog, 3′-deoxycytidine
triphosphate (3′-dCTP) (Sigma Aldrich) was also added as a positive
control. The reaction mixtures were incubated at 30 °C for 120 min
and stopped by the addition of 50 mM EDTA and 0.5% SDS. The RNA
products were recovered by phenol–chloroform extraction and
ethanol precipitation following removal of proteins by proteinase K
digestion. The RNA products were denatured in glyoxal sample
loading buffer and resolved in a 1% agarose gel using 10× RNA running
buffer (Ambion). An agarose gel was dried using a GelAir drying
system (Bio-Rad) and exposed to a phosphorimager for 4 h.Mammalian two-hybrid experiment
Equal amounts of pAct-NS5A, pBind-NS5A, and pG5-Luc were
transfected into Huh7.5 cells by using a lipofectamine 2000
transfection reagent (Invitrogen) as described by the manufacturer.
Transfected cells were plated onto a 96-well plate and supplemented
with DMSO or 10 nM of BMS-790052. At 2 days after incubation,
ﬁreﬂy and Renilla luciferase activities were measured by using a
dual glow luciferase kit (Promega). The Renilla luciferase activity was
used to normalize transfection efﬁciency. The ﬁreﬂy luciferase activity
from pAct-Myo and pBind-ID cotransfection was deﬁned as 1 to plot
the ﬁreﬂy luciferase activity from pAct-NS5A and pBind-NS5A
cotransfection.
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